| Emily P Carter, AA | |
|
1 Hospital Dr Sw, Huntsville, AL 35801-6455 | |
| (256) 429-5071 | |
| (256) 880-6712 |
| Full Name | Emily P Carter |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 15 Years |
| Location | 1 Hospital Dr Sw, Huntsville, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578795282 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (Missouri) | Secondary |
| 367H00000X | Anesthesiologist Assistant | AA.844 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Comprehensive Anesthesia Services Pc | 8123081429 | 42 |
News Archive
For the first time, structural biologists have managed to obtain the detailed three-dimensional structure of one of the proteins that form the core of the complex molecular machine, called the replisome, that plant and animal cells assemble to copy their DNA as the first step in cell reproduction.
Wealth, population size, race and age associate with the supply of hospice care available in a county, according to a study published in the Journal of Pain and Symptom Management this month.
QR Pharma, Inc. , a developer of novel drugs to treat Alzheimer's disease, announced today that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
People who have reduced enzyme activity to breakdown active aldehyde, i.e., those who become easily inebriated, are more likely to develop fatty liver disease even if they do not drink alcohol.
› Verified 2 days ago
| Entity Name | Huntsville Anesthesiology Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073661492 PECOS PAC ID: 0749171262 Enrollment ID: O20040323001826 |
News Archive
For the first time, structural biologists have managed to obtain the detailed three-dimensional structure of one of the proteins that form the core of the complex molecular machine, called the replisome, that plant and animal cells assemble to copy their DNA as the first step in cell reproduction.
Wealth, population size, race and age associate with the supply of hospice care available in a county, according to a study published in the Journal of Pain and Symptom Management this month.
QR Pharma, Inc. , a developer of novel drugs to treat Alzheimer's disease, announced today that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
People who have reduced enzyme activity to breakdown active aldehyde, i.e., those who become easily inebriated, are more likely to develop fatty liver disease even if they do not drink alcohol.
› Verified 2 days ago
| Entity Name | Comprehensive Anesthesia Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194704742 PECOS PAC ID: 8123081429 Enrollment ID: O20041108000892 |
News Archive
For the first time, structural biologists have managed to obtain the detailed three-dimensional structure of one of the proteins that form the core of the complex molecular machine, called the replisome, that plant and animal cells assemble to copy their DNA as the first step in cell reproduction.
Wealth, population size, race and age associate with the supply of hospice care available in a county, according to a study published in the Journal of Pain and Symptom Management this month.
QR Pharma, Inc. , a developer of novel drugs to treat Alzheimer's disease, announced today that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
People who have reduced enzyme activity to breakdown active aldehyde, i.e., those who become easily inebriated, are more likely to develop fatty liver disease even if they do not drink alcohol.
› Verified 2 days ago
| Entity Name | Physynergy Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134465560 PECOS PAC ID: 6204081292 Enrollment ID: O20130222000456 |
News Archive
For the first time, structural biologists have managed to obtain the detailed three-dimensional structure of one of the proteins that form the core of the complex molecular machine, called the replisome, that plant and animal cells assemble to copy their DNA as the first step in cell reproduction.
Wealth, population size, race and age associate with the supply of hospice care available in a county, according to a study published in the Journal of Pain and Symptom Management this month.
QR Pharma, Inc. , a developer of novel drugs to treat Alzheimer's disease, announced today that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
People who have reduced enzyme activity to breakdown active aldehyde, i.e., those who become easily inebriated, are more likely to develop fatty liver disease even if they do not drink alcohol.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily P Carter, AA P.o. Box 52404, Lafayette, LA 70505-6484 Ph: (256) 880-6711 | Emily P Carter, AA 1 Hospital Dr Sw, Huntsville, AL 35801-6455 Ph: (256) 429-5071 |
News Archive
For the first time, structural biologists have managed to obtain the detailed three-dimensional structure of one of the proteins that form the core of the complex molecular machine, called the replisome, that plant and animal cells assemble to copy their DNA as the first step in cell reproduction.
Wealth, population size, race and age associate with the supply of hospice care available in a county, according to a study published in the Journal of Pain and Symptom Management this month.
QR Pharma, Inc. , a developer of novel drugs to treat Alzheimer's disease, announced today that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
People who have reduced enzyme activity to breakdown active aldehyde, i.e., those who become easily inebriated, are more likely to develop fatty liver disease even if they do not drink alcohol.
› Verified 2 days ago
Jerome Henley, AA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 721 Madison St Se, Huntsville, AL 35801 Phone: 256-533-4888 | |
Trenton Crouch, CAA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 721 Madison St Se, Huntsville, AL 35801 Phone: 256-533-4888 |